Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Open accessThe DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities. AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses. Additionally, several risk factors such as increasing age, genetic factors, head injuries, vascular diseases, infections, and environmental factors play a role in the disease. Currently, there are only two classes of approved drugs to treat AD, including inhibitors to cholinesterase enzyme and antagonists to N-methyl d-aspartate (NMDA), which are effective only in treating the symptoms of AD, but do not cure or prevent the disease. Nowadays, the research is focusing on understanding AD pathology by targeting several mechanisms, such as abnormal tau protein metabolism, β-amyloid, inflammatory response, and cholinergic and free radical damage, aiming to develop successful treatments that are capable of stopping or modifying the course of AD. This review discusses currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), chaperones, and natural compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by neurodegeneration due to neuronal cell death, starting in the entorhinal cortex of the hippocampus, primarily affecting individuals aged 65 and older [1].”
From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For ADs, precision medicine focuses on genetic and biomarker analysis to improve therapy approaches, risk assessment, and diagnosis.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They may also be the cause of neuroinflammation by activating microglia and producing inflammatory cytokines.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Early in AD progression, damage to neuronal connections occurs primarily in the medial temporal lobe and neocortical areas (Figure 2B) [42,43].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“The first disease-modifying medication for AD is a recombinant monoclonal antibody called aducanumab, also known by the brand name Aduhelm. It targets amyloid beta specifically [37]. It functions by lowering the quantity of amyloid deposits or brain plaques [130,131].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 2×
“At present, there is no cure for Alzheimer’s disease, although there are available treatments that just improve the symptoms [6,7].”
BackgroundRetractedTacrine for Alzheimer's disease
Qizilbash, N., Birks, J., Arrieta, J. L., Lewington, S., & Szeto, S. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000202 · Cited by 85
RetractedLi, J.-G., Chiu, J., & Praticò, D. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0364-x · Cited by 58
RetractedRETRACTED ARTICLE: VPS35 regulates tau phosphorylation and neuropathology in tauopathy
Vagnozzi, A. N., Li, J.-G., Chiu, J., Razmpour, R., Warfield, R., Ramirez, S. H., & Praticò, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0453-x · Cited by 36
RetractedMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“These changes also appear in normal aging, which makes it difficult to distinguish the cases in early AD [43,44].”
BackgroundThe cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
Alzheimer's disease: Targeting the Cholinergic System
H. Ferreira-Vieira, T., M. Guimaraes, I., R. Silva, F., & M. Ribeiro, F. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150716165726 · Cited by 1,551
The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Epidemiology of Alzheimer Disease
Mayeux, R., & Stern, Y. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006239 · Cited by 1,064
Review Article: Genetics of Alzheimer Disease
Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383571 · Cited by 1,029
Role of Glutamate and NMDA Receptors in Alzheimer’s Disease
Wang, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160763 · Cited by 1,009
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · cited 3×
“Targeting these pathways may give potential therapeutic agents for AD [6].”
BackgroundThe genetic landscape of Alzheimer disease: clinical implications and perspectives
Van Cauwenberghe, C., Van Broeckhoven, C., & Sleegers, K. (2016) · Genetics in Medicine · doi:10.1038/gim.2015.117 · Cited by 863
Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease
Kametani, F., & Hasegawa, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00025 · Cited by 836
Neuropathology of Alzheimer's Disease
Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825
A review on cholinesterase inhibitors for Alzheimer’s disease
Anand, P., & Singh, B. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0036-3 · Cited by 709
Clinical trials of new drugs for Alzheimer disease
Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702
Alzheimer’s disease prevention: from risk factors to early intervention
Crous-Bou, M., Minguillón, C., Gramunt, N., & Molinuevo, J. L. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0297-z · Cited by 687
Age, APOE and sex: triad of risk of Alzheimer’s disease.
Riedel, B. C., Thompson, P. M., & Brinton, R. D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.012 · Cited by 627
Lanoiselée, H.-M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A.-C., Pasquier, F., Rollin-Sillaire, A., Martinaud, O., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002270 · Cited by 616
Risk factors for Alzheimer’s disease
A. Armstrong, R. (2019) · Folia Neuropathologica · doi:10.5114/fn.2019.85929 · Cited by 606
Cholinesterase inhibitors as Alzheimer's therapeutics (Review)
Sharma, K. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10374 · Cited by 602
Drug treatments in Alzheimer’s disease
Briggs, R., Kennelly, S. P., & O’Neill, D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-247 · Cited by 571
Alzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557
The Role of NMDA Receptors in Alzheimer’s Disease
Liu, J., Chang, L., Song, Y., Li, H., & Wu, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00043 · Cited by 535
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Dementia of the Alzheimer Type
Terry, R. D., & Davies, P. (1980) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.03.030180.000453 · Cited by 529
Metal Toxicity Links to Alzheimer's Disease and Neuroinflammation
Huat, T. J., Camats-Perna, J., Newcombe, E. A., Valmas, N., Kitazawa, M., & Medeiros, R. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.01.018 · Cited by 470
Santos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431
The age factor in Alzheimer’s disease
Guerreiro, R., & Bras, J. (2015) · Genome Medicine · doi:10.1186/s13073-015-0232-5 · Cited by 415
De-Paula, V. J., Radanovic, M., Diniz, B. S., & Forlenza, O. V. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_14 · Cited by 405
The Infectious Etiology of Alzheimer’s Disease
Sochocka, M., Zwolińska, K., & Leszek, J. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170313122937 · Cited by 399
Galantamine: A Review of its Use in Alzheimer??s Disease
Scott, L. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200060050-00008 · Cited by 383
Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies
Foster, E. M., Dangla-Valls, A., Lovestone, S., Ribe, E. M., & Buckley, N. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00164 · Cited by 381
The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Ricciarelli, R., & Fedele, E. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170116143743 · Cited by 380
Tolar, M., Abushakra, S., Hey, J. A., Porsteinsson, A., & Sabbagh, M. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00663-w · Cited by 354
De Strooper, B. (2007) · EMBO reports · doi:10.1038/sj.embor.7400897 · Cited by 351
Metals and Alzheimer's disease
Adlard, P. A., & Bush, A. I. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-102-303 · Cited by 324
Cardiovascular disease and Alzheimer's disease: common links
STAMPFER, M. J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01687.x · Cited by 324
Cardiovascular risk factors and future risk of Alzheimer’s disease
de Bruijn, R. F., & Ikram, M. A. (2014) · BMC Medicine · doi:10.1186/s12916-014-0130-5 · Cited by 322
Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein.
Cras, P., Kawai, M., Lowery, D., Gonzalez-DeWhitt, P., Greenberg, B., & Perry, G. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7552 · Cited by 319
Rivastigmine for Alzheimer's disease
Birks, J., Grimley Evans, J., Iakovidou, V., & Tsolaki, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub2 · Cited by 296
Air Pollution, Oxidative Stress, and Alzheimer's Disease
Moulton, P. V., & Yang, W. (2012) · Journal of Environmental and Public Health · doi:10.1155/2012/472751 · Cited by 265
Presenilin-1 mutations and Alzheimer’s disease.
Kelleher, R. J., & Shen, J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619574114 · Cited by 255
The cholinergic hypothesis of Alzheimer's disease: a review of progress
BABIC;, T., FRANCIS, P. T., PALMER, A. M., SNAPE, M., & WILCOCK, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.4.558 · Cited by 255
The therapeutic potential of chemical chaperones in protein folding diseases
Cortez, L., & Sim, V. (2014) · Prion · doi:10.4161/pri.28938 · Cited by 254
Memantine for the Treatment of Dementia: A Review on its Current and Future Applications
Folch, J., Busquets, O., Ettcheto, M., Sánchez-López, E., Castro-Torres, R. D., Verdaguer, E., Garcia, M. L., Olloquequi, J., Casadesús, G., Beas-Zarate, C., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170672 · Cited by 245
Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease
Overk, C. R., & Masliah, E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.015 · Cited by 242
Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease
TCW, J., & Goate, A. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024539 · Cited by 242
Andrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. D. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092313 · Cited by 240
Lleó, A., Núñez-Llaves, R., Alcolea, D., Chiva, C., Balateu-Paños, D., Colom-Cadena, M., Gomez-Giro, G., Muñoz, L., Querol-Vilaseca, M., Pegueroles, J., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.001290 · Cited by 219
Tacrine: First Drug Approved for Alzheimer's Disease
Crismon, M. L. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402800612 · Cited by 218
Obesity as a risk factor for Alzheimer's disease: weighing the evidence
Alford, S., Patel, D., Perakakis, N., & Mantzoros, C. S. (2018) · Obesity Reviews · doi:10.1111/obr.12629 · Cited by 217
Pharmacological chaperones stabilize retromer to limit APP processing
Mecozzi, V. J., Berman, D. E., Simoes, S., Vetanovetz, C., Awal, M. R., Patel, V. M., Schneider, R. T., Petsko, G. A., Ringe, D., & Small, S. A. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1508 · Cited by 216
Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease
Tarawneh, R., D’Angelo, G., Crimmins, D., Herries, E., Griest, T., Fagan, A. M., Zipfel, G. J., Ladenson, J. H., Morris, J. C., & Holtzman, D. M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0086 · Cited by 215
Nutrition and the Risk of Alzheimer's Disease
Hu, N., Yu, J.-T., Tan, L., Wang, Y.-L., Sun, L., & Tan, L. (2013) · BioMed Research International · doi:10.1155/2013/524820 · Cited by 209
The significance of environmental factors in the etiology of Alzheimer's disease
Grant, W. B., Campbell, A., Itzhaki, R. F., & Savory, J. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4308 · Cited by 208
Apostolova, L. G. (2016) · Continuum · doi:10.1212/con.0000000000000307 · Cited by 198
Neurofibrillary Tangles and Alzheimer’s Disease
Brion, J.-P. (1998) · European Neurology · doi:10.1159/000007969 · Cited by 193
Alzheimer and his disease: a brief history
Cipriani, G., Dolciotti, C., Picchi, L., & Bonuccelli, U. (2011) · Neurological Sciences · doi:10.1007/s10072-010-0454-7 · Cited by 193
Schachter, A. S., & Davis, K. L. (2000) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2000.2.2/asschachter · Cited by 192
Donepezil: A Review of its Use in Alzheimer??s Disease
Dooley, M., & Lamb, H. M. (2000) · Drugs & Aging · doi:10.2165/00002512-200016030-00005 · Cited by 189
Diabetes and Alzheimer's Disease: Mechanisms and Nutritional Aspects
Lee, H. J., Seo, H. I., Cha, H. Y., Yang, Y. J., Kwon, S. H., & Yang, S. J. (2018) · Clinical Nutrition Research · doi:10.7762/cnr.2018.7.4.229 · Cited by 189
Understanding the Amyloid Hypothesis in Alzheimer’s Disease
Paroni, G., Bisceglia, P., & Seripa, D. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180802 · Cited by 187
Singh, S. K., Srivastav, S., Yadav, A. K., Srikrishna, S., & Perry, G. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7361613 · Cited by 186
Walker, E. S., Martinez, M., Brunkan, A. L., & Goate, A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02858.x · Cited by 177
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809316 · Cited by 177
Heat Shock Proteins in Alzheimer’s Disease: Role and Targeting
Campanella, C., Pace, A., Caruso Bavisotto, C., Marzullo, P., Marino Gammazza, A., Buscemi, S., & Palumbo Piccionello, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092603 · Cited by 174
Role of apolipoprotein E in neurodegenerative diseases
Van Giau, V., Bagyinszky, E., An, S. S., & Kim, S. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84266 · Cited by 171
The genes associated with early-onset Alzheimer’s disease
Dai, M.-H., Zheng, H., Zeng, L.-D., & Zhang, Y. (2018) · Oncotarget · doi:10.18632/oncotarget.23738 · Cited by 167
The Epigenetics of Alzheimer’s Disease: Factors and Therapeutic Implications
Liu, X., Jiao, B., & Shen, L. H. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00579 · Cited by 167
An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine
Khoury, R., Rajamanickam, J., & Grossberg, G. T. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617750555 · Cited by 165
Donepezil in Alzheimer’s disease: from conventional trials to pharmacogenetics
Cacabelos, R. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a908 · Cited by 164
Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease
Zhao, J., Liu, X., Xia, W., Zhang, Y., & Wang, C. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00137 · Cited by 162
Alzheimer's Disease: Diagnosis and Treatment Across the Spectrum of Disease Severity
Neugroschl, J. A., & Wang, S. (2011) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20279 · Cited by 160
The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease.
Armstrong, R. A. (2009) · PubMed · Cited by 160
Kempf, S., & Metaxas, A. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.193234 · Cited by 160
Rivastigmine for Alzheimer's disease
Birks, J., Grimley Evans, J., Iakovidou, V., & Tsolaki, M. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191 · Cited by 159
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study
Vandenberghe, R. R., Riviere, M., Caputo, A., Sóvágó, J., Maguire, R. P., Farlow, M. R., Marotta, G., Sánchez‐Valle, R., Scheltens, P., Ryan, J. M., et al. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.12.003 · Cited by 157
A review of estrogen receptor α gene (ESR1) polymorphisms, mood, and cognition
Sundermann, E. E., Maki, P. M., & Bishop, J. R. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181df4a19 · Cited by 156
An Overview on the Clinical Development of Tau-Based Therapeutics
Medina, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041160 · Cited by 156
Aluminum and Alzheimer’s Disease
Colomina, M. T., & Peris‐Sampedro, F. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-60189-2_9 · Cited by 150
Disease-modifying treatments for Alzheimer’s disease
Galimberti, D., & Scarpini, E. A. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611404470 · Cited by 149
Holler, C. J., Davis, P. R., Beckett, T. L., Platt, T. L., Webb, R. L., Head, E., & Murphy, M. P. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-132450 · Cited by 145
Wilhelmus, M. M. M., de Waal, R. M. W., & Verbeek, M. M. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0029-7 · Cited by 144
ATP-binding cassette transporter A1: From metabolism to neurodegeneration
Koldamova, R., Fitz, N. F., & Lefterov, I. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.007 · Cited by 144
Eldufani, J., & Blaise, G. A. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.03.004 · Cited by 141
Loss‐of‐function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease
Nordestgaard, L. T., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.04.006 · Cited by 139
DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASE
Cummings, J., & Fox, N. (2017) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2017.12 · Cited by 139
Fülöp, T., Itzhaki, R. F., Balin, B. J., Miklossy, J., & Barron, A. E. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00362 · Cited by 137
Interactome mapping suggests new mechanistic details underlying Alzheimer's disease
Soler‐López, M., Zanzoni, A., Lluís, R., Stelzl, U., & Aloy, P. (2010) · Genome Research · doi:10.1101/gr.114280.110 · Cited by 135
Hsp90 and Its Co-Chaperones in Neurodegenerative Diseases
Bohush, A., Bieganowski, P., & Filipek, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20204976 · Cited by 132
Does Obesity Increase the Risk of Dementia: A Literature Review
Anjum, I., Fayyaz, M., Abdullah, W., Sohail, W., & Ali, A. (2018) · Cureus · doi:10.7759/cureus.2660 · Cited by 130
Galantamine for Alzheimer's disease
Prvulovic, D., Hampel, H. J., & Pantel, J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003592137 · Cited by 124
Heat Shock Protein 90 in Alzheimer’s Disease
Ou, J.-R., Tan, M., Xie, A., Yu, J., & Tan, L. (2014) · BioMed Research International · doi:10.1155/2014/796869 · Cited by 116
Alzheimer’s disease: A metabolic systems degeneration?
Blass, J. P., & Zemcov, A. (1984) · Neurochemical Pathology · doi:10.1007/bf02834249 · Cited by 114
Disease-modifying drugs in Alzheimer's disease
Scarpini, E. A., Galimberti, D., & Ghezzi, L. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s41431 · Cited by 113
An, S. S. A., Cai, Y., & Kim, S. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s85808 · Cited by 112
Estrogen receptor β in Alzheimer’s disease: From mechanisms to therapeutics
Zhao, L., Woody, S. K., & Chhibber, A. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.08.001 · Cited by 111
Abisambra, J. F., Jinwal, U. K., Miyata, Y., Rogers, J. T., Blair, L. J., Li, X., Seguin, S. P., Wang, L., Jin, Y. L., Bacon, J. A., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.02.027 · Cited by 110
Nutrition and AGE‐ing: Focusing on Alzheimer’s Disease
Abate, G., Marziano, M., Rungratanawanich, W., Memo, M., & Uberti, D. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/7039816 · Cited by 103
Pegueroles, J., Initiative, A. D. N., Jiménez, A., Vilaplana, E., Montal, V., Carmona‐Iragui, M., Pané, A., Alcolea, D. A., Videla, L., Casajoana, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26162 · Cited by 99
Low Vitamin B12 Levels: An Underestimated Cause Of Minimal Cognitive Impairment And Dementia
Jatoi, S., Hafeez, D. A., Riaz, S. U., Ali, A., Ghauri, M. I., & Zehra, M. (2020) · Cureus · doi:10.7759/cureus.6976 · Cited by 96
NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease
Huang, Y.-J., Lin, C., Lane, H., & Tsaid, G. E. (2012) · Current Neuropharmacology · doi:10.2174/157015912803217288 · Cited by 92
Calderwood, S. K., & Murshid, A. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00192 · Cited by 91
Wattmo, C., Minthon, L., & Wallin, Å. K. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0174-1 · Cited by 83
Yaffe, K. S., Lindquist, K. J., Sen, S., Cauley, J. A., Ferrell, R. E., Penninx, B. W. J. H., Harris, T. B., Li, R., & Cummings, S. R. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.003 · Cited by 81
Croze, M. L., & Zimmer, L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170857 · Cited by 78
Role of water‐soluble amyloid‐β in the pathogenesis of Alzheimer's disease
Tabaton, M., & Piccini, A. (2005) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2005.00428.x · Cited by 77
Li, N.-M., Li, N., Liu, K., Zhang, H.-H., Nakanishi, H., & Qing, H. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.247469 · Cited by 76
Li, J.-G., Chiu, J., Ramanjulu, M., Blass, B. E., & Praticò, D. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0350-4 · Cited by 74
Rivastigmine in the treatment of patients with Alzheimer's disease
Müller, T. H. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2007.3.2.211 · Cited by 70
Diagnosis and Treatment of Alzheimers Disease
Monczor, M. (2005) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1568015053202723 · Cited by 68
Wang, B., Liu, Y., Huang, L., Chen, J., Li, J. J., Wang, R., Kim, E., Chen, Y., Justicia, C., Sakata, K., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.104 · Cited by 67
A Novel NMDA Receptor Antagonist Protects against Cognitive Decline Presented by Senescent Mice
Companys‐Alemany, J., Turcu, A. L., Bellver‐Sanchís, A., Loza, M. I., Brea, J. M., Canudas, A. M., Leiva, R., Vázquez, S., Pallàs, M., & Griñán‐Ferré, C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030284 · Cited by 63
Targeting Allosteric Control Mechanisms in Heat Shock Protein 70 (Hsp70)
Li, X., Shao, H., Taylor, I. R., & Gestwicki, J. E. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160413140911 · Cited by 60
Environmental factors in the development and progression of late-onset Alzheimer’s disease
Wainaina, M. N., Chen, Z., & Zhong, C. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1425-9 · Cited by 58
Genetic of Alzheimer's Disease: A Narrative Review Article.
Khanahmadi, M., Farhud, D. D., & Malmir, M. (2015) · PubMed Central · Cited by 56
Andrew, R. J., De Rossi, P., Nguyen, P., Kowalski, H. R., Recupero, A. J., Guerbette, T., Krause, S. V., Rice, R. C., Laury-Kleintop, L., Wagner, S. L., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006379 · Cited by 55
Schachter, A. S., & Davis, K. L. (2000) · PubMed Central · Cited by 52
Soler‐López, M., Badiola, N., Zanzoni, A., & Aloy, P. (2012) · BioEssays · doi:10.1002/bies.201100193 · Cited by 50
Wahba, S. M. R., Darwish, A. S., & Kamal, S. M. (2016) · Materials Science and Engineering C · doi:10.1016/j.msec.2016.04.041 · Cited by 50
Bi, C., Bi, S., & Li, B. (2018) · Aging and Disease · doi:10.14336/ad.2018.0425 · Cited by 50
Therapeutic Effects of Natural Drugs on Alzheimer’s Disease
Ma, Y., Yang, M., Li, X., Yue, J.-W., Chen, J., Yang, M.-W., Huang, X., Zhu, L., Hong, F., & Yang, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01355 · Cited by 49
Alzheimer's Disease: Clinical Features, Pathogenesis, and Treatment
Rathmann, K. L., & Conner, C. S. (1984) · Annals of Pharmacotherapy · doi:10.1177/106002808401800902 · Cited by 48
Koyama, A., Hashimoto, M., Tanaka, H., Fujise, N., Matsushita, M., Miyagawa, Y., Hatada, Y., Fukuhara, R., Hasegawa, N., Todani, S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157053 · Cited by 48
Cho, H. S., Huang, L. K., Lee, Y. T., Chan, L., & Hong, C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00325 · Cited by 44
Blass, J. P. (1985) · Disease-a-Month · doi:10.1016/0011-5029(85)90025-2 · Cited by 35
Wi, S. M., Park, J., Shim, J., Chun, E., & Lee, K. (2014) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-08-1277 · Cited by 34
Martín-Peña, A., Rincón-Limas, D. E., & Fernandez-Fúnez, P. (2018) · Scientific Reports · doi:10.1038/s41598-018-28341-w · Cited by 34
Rivastigmine in Alzheimer's disease: Cognitive function and quality of life.
Annicchiarico, R., Federici, A., Pettenati, C., & Caltagirone, C. (2007) · PubMed Central · Cited by 32
Screening strategies to identify HSP70 modulators to treat Alzheimer’s disease
Repalli, J., & Meruelo, D. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s72165 · Cited by 32
Knight, E. M., Williams, H. N., Stevens, A. C., Kim, S. H., Kottwitz, J., Morant, A., Steele, J., Klein, W. L., Yanagisawa, K., BOYD, R. E., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.135 · Cited by 29
Pharmacological aspects of galantamine for the treatment of Alzheimer's disease
Kim, J. K., & Park, S. U. (2017) · EXCLI journal · doi:10.17179/excli2016-820 · Cited by 28
Updates to Diagnostic Guidelines for Alzheimer’s Disease
Yaari, R., Fleisher, A., & Tariot, P. N. (2011) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.11f01262 · Cited by 26
Vitamin D Receptor (VDR) Polymorphisms and Late-Onset Alzheimer's Disease: An Association Study.
Khorshid, H. R. K., Gozalpour, E., Saliminejad, K., Karimloo, M., Ohadi, M., & Kamali, K. (2013) · PubMed Central · Cited by 22
In Vivo Validation of a Small Molecule Inhibitor of Tau Self-Association in htau Mice
Davidowitz, E. J., Krishnamurthy, P., Lopez, P. L. D. C., Jimenez, H. T., Adrien, L. R., Davies, P., & Moe, J. G. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190465 · Cited by 19
Study of Estrogen Receptor-α and Receptor-β Gene Polymorphisms on Alzheimer's Disease
Goumidi, L., Dahlman‐Wright, K., Tapia‐Páez, I., Matsson, H., Pasquier, F., Amouyel, P., Kere, J., Lambert, J., & Meirhaeghe, A. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110362 · Cited by 17
Schachter, A. S., & Davis, K. L. (2000) · Current Treatment Options in Neurology · doi:10.1007/s11940-000-0023-0 · Cited by 15
Muzambi, R., Bhaskaran, K., Brayne, C., Smeeth, L., & Warren-Gash, C. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030874 · Cited by 11
Research works printed but not linked: 4
- Kumar, A., Sidhu, J., and Goyal, A. (2020). Alzheimer Disease. StatPearls, StatPearls Publishing. Available online: https://www.ncbi.nlm.nih.gov/books/NBK499922/.
- Singh, R., and Sadiq, N.M. (2020). Cholinesterase Inhibitors. StatPearls, StatPearls Publishing. Available online: https://www.ncbi.nlm.nih.gov/books/NBK544336/.
- Kuns, B., Rosani, A., and Varghese, D. (2020). Memantine. StatPearls, StatPearls Publishing. Available online: https://www.ncbi.nlm.nih.gov/books/NBK500025/.
- Kumar, A., and Sharma, S. (2020). Donepezil. StatPearls, StatPearls Publishing. Available online: https://www.ncbi.nlm.nih.gov/books/NBK513257/.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Clinical applications of stem cell-derived exosomes
Tan, F., Li, X., Wang, Z., Li, J., Shahzad, K., & Zheng, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01704-0 · Cited by 708
Inflammatory Processes in Alzheimer’s Disease—Pathomechanism, Diagnosis and Treatment: A Review
Twarowski, B., & Herbet, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076518 · Cited by 412
Gadhave, D. G., Sugandhi, V. V., Jha, S. K., Nangare, S. N., Gupta, G., Singh, S. K., Dua, K., Cho, H., Hansbro, P. M., & Paudel, K. R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102357 · Cited by 358
Więckowska-Gacek, A., Mietelska-Porowska, A., Wydrych, M., & Wojda, U. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101397 · Cited by 343
“…molecular mechanisms, several additional hypotheses of AD pathogenesis have been proposed including cholinergic, oxidative stress, mitochondrial cascade, calcium dyshomeostasis, neurovascular and lymphatic system hypotheses (Breijyeh and Karaman, 2020; Liu et al., 2019a; Wojsiat et al., 2018).”
Metadata
- Authors
- Breijyeh, Z., & Karaman, R.
- Affiliations
- Al-Quds University (PS)
- Corresponding author
- Karaman, Rafik
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-12-08
- Volume
- 25
- Issue
- 24
- Pages
- 5789
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7764106
- OpenAlex
- W3112948680
- Cited by
- 2,789
- References
- 149
- Citations by year
- 2026: 418 · 2025: 708 · 2024: 733 · 2023: 541 · 2022: 310 · 2021: 79
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, dementia, cholinergic hypothesis, amyloid hypothesis, risk factors, cholinesterase inhibitors, NMDA receptor antagonists, tau protein, amyloid-beta, neuroinflammation, oxidative stress, disease-modifying therapy, molecular chaperones, natural compounds, drug development
- MeSH terms
- Alzheimer Disease, Animals, Disease Susceptibility, Humans, Risk Factors, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Risk Assessment, Disease Management, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.